SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Reports of abrupt layoffs affecting roughly 550 workers in India, with additional cuts in the Philippines, have raised fears that a client project was scaled back and could weigh on revenue, particularly given Innodatas customer concentration; the company has not clarified the impact. Traders are divided between viewing the selloff as an overreaction or an efficiency shift and worrying about a lost major account, with many awaiting earnings and managements explanation.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotles quarterly report sparked a rally after same-store sales growth topped expectations, though earnings fell short and margins weakened. Traders are watching whether the post-report momentum continues, while others remain cautious about softer sales trends and cost pressures.

World Liberty Financial (WLFI) is a cryptocurrency launched in 2025and operates on the Ethereum platform. World Liberty Financial has a current supply of 100,000,000,000 with 31,779,991,497 in circulation. The last known price of World Liberty Financial is 0.05007445 USD and is up 0.02 over the last 24 hours. It is currently trading on 491 active market(s) with $20,910,403.62 traded over the last 24 hours. More information can be found at https://www.worldlibertyfinancial.com/.

WorldFinancial

WLFI is drawing attention around speculation that a bank charter and expanded USD1 stablecoin use could support a rebound, with bullish traders also pointing to limited circulating supply. Others are skeptical, citing the tokens weak performance and concerns that the Trump family has profited while holders absorb losses.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circles CFO is preparing to step down, while co-founder and director Sean Neville has resigned from the board, prompting concern about leadership stability. Traders disagree on whether the departures are an orderly transition or a warning sign, with USDC growth and competition also weighing on sentiment.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladocs Q3 results, with improving profitability, margins and cash generation, drove a sharp rebound and fueled speculation that heavy short interest could amplify the move. Bulls see signs of a turnaround, while skeptics point to declining revenue and BetterHelps ongoing weakness and question whether the rally is justified.

Pump.fun (PUMP) is a cryptocurrency launched in 2025and operates on the Solana platform. Pump.fun has a current supply of 824,932,291,477.509362 with 460,045,468,948.538529 in circulation. The last known price of Pump.fun is 0.00419537 USD and is up 0.39 over the last 24 hours. It is currently trading on 413 active market(s) with $87,549,521.45 traded over the last 24 hours. More information can be found at https://pump.fun/.

Pump.fun

PUMP.fun is drawing attention for a volatile rebound and anticipated breakout, with traders highlighting the tokens buyback-and-burn mechanism and the platforms activity as bullish arguments. Others remain skeptical, pointing to sharp selloffs, weak participation, and the risks of meme-coin speculation.

XPeng, Inc. is a global physical AI company, which engages in bringing artificial intelligence into the physical world to reshape future mobility and smart living. It developed a full-stack physical AI architecture spanning Turing AI chips, world foundation models, and integrated software and hardware applications. The firm's product portfolio includes smart EVs, robotaxis, and humanoid robots. The company's sales and services drives continuous technological innovation and fosters an open physical AI ecosystem, making life smarter, safer, and better for users worldwide. XPeng, Inc. was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPengs October delivery update is driving attention, with traders highlighting record deliveries and rapid overseas growth while watching whether that pace can support the companys Q4 outlook. The reaction is mixed: some see evidence of growth momentum, while others question margins and profitability amid continued weakness in the shares.

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and décor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

Home Depot is drawing attention for a recent technical rebound, with traders highlighting a breakout that held and discussing bullish swing trades and call options. Others question the rally given high rates and weak housing conditions, framing the move as sector rotation rather than evidence of a housing recovery.

iShares Trust - iShares 7-10 Year Treasury Bond ETF

iShares 7-10 Year Treasury Bond ETF

Treasury-yield volatility and uncertainty over the Feds rate path dominate discussion, with inflation, fiscal borrowing and AI-related debt financing adding to concerns about pressure on Treasuries. Traders are divided between expecting higher-for-longer yields to weigh on IEF and anticipating a bond rebound if yields ease.

Mobileye Global, Inc. engages in the business of developing and deploying driver assistance systems and autonomous driving technologies and solutions. It operates under the Mobileye and Other segments. The company was founded by Amnon Shashua and Ziv Aviram in 1999 and is headquartered in Jerusalem, Israel.

Mobileye Global Inc - Ordinary Shares - Class A

MOBILEYE GLOBAL INC

Mobileyes post-earnings selloff and new 52-week low dominate discussion, despite traders noting an earnings beat and a modestly improved outlook. The bearish reaction reflects concerns about weak underlying growth, limited traction in higher-end driver-assistance programs, and competition; some holders argue the results and cash position make the decline excessive.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE

Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE PR Newswire MIAMI, July 29, 2026 MIAMI, July 29, 2026 /PRNewswire/ -- Global law firm Greenberg Traurig, P.A.advised Entera Bio Ltd. (NASDAQ: ENTX), a...

12 Health Care Stocks Moving In Monday's Intraday Session

Gainers

Entera Bio (NASDAQ:ENTX) stock moved upwards by 86.6% to $3.83 during Monday's regular session. The company's market cap stands at $100.9 million.
Gossamer Bio (NASDAQ:GOSS) shares moved upwards byread more...

Entera Bio Stock Rallies 35% in a Month: Here's What You Should Know

ENTX stock jumps 35% in a month after the FDA backs a streamlined phase III plan for oral osteoporosis candidate EB613, bringing a key regulatory milestone into focus.

Take the Zacks Approach to Beat the Market: Dell, Caterpillar, Amkor in Focus

DELL, CAT and AMKR led standout gains as Zacks highlighted top-performing portfolios amid volatile markets and inflation worries.

ENTX Stock On Track For Best Day In Over 5 Years — What’s Driving The Rally?

Equity

Entera said that the FDA backed its plan for a single large late-stage clinical trial of its experimental once-daily pill, EB613, for postmenopausal women with osteoporosis.


Entera Bio (ENTX) to Release Earnings on Friday

Entera Bio (NASDAQ:ENTX) will be releasing its Q1 2026 earnings after the market closes on Friday, May 8. (View Earnings Report at...

Entera Bio (ENTX) Upgraded to Buy: Here's What You Should Know

Entera Bio (ENTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What is HC Wainwright's Estimate for Entera Bio Q1 Earnings?

Entera Bio Ltd. (NASDAQ:ENTX - Free Report) - Analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for Entera Bio in a research report issued to clients and investors on Monday, April 27th. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings of ($0...

HC Wainwright Has Lowered Expectations for Entera Bio (NASDAQ:ENTX) Stock Price

HC Wainwright lowered their price objective on shares of Entera Bio from $10.00 to $9.00 and set a "buy" rating on the stock in a research note on Monday...

Entera Bio Touts EB613 Oral Anabolic Tablet as Osteoporosis Care Gap Persists, Phase III Near

Entera Bio (NASDAQ:ENTX) executives and physician panelists used a roundtable discussion to highlight what they described as persistent gaps in osteoporosis care and the potential role for the...

Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. It s pipeline include PTH(1-34), GLP-1 and GLP-2. The company was founded on September 30, 2009 and is headquartered in Jerusalem, Israel.

Entera Bio Ltd

Bearish Sentiment

<ul class="summary-bullets"><li>The main measure of success in the upcoming trial will be how much bone density improves in the hip after one year of treatment.</li><li>Entera expects to begin the trial in late 2026 and report top-line results in the second half of 2028 — about a year earlier than previously planned.</li><li>The company’s earlier mid-stage study of the pill in 161 postmenopausal women met its goals, showing meaningful increases in bone density at the spine and hip.</li></ul>Shares of Entera Bio Ltd. (ENTX) surged 52% on Monday after the company announced encouraging feedback from the U.S. Food and Drug Administration on its registrational late-stage study design for its most advanced program, EB613.The stock is on track for its best day since March 2021, if gains hold.<h2 class="st-heading-2">FDA Aligns With Entera</h2>The FDA backed Entera’s plan for a single large late-stage clinical trial of its experimental once-daily pill, EB613, for postmenopausal women with osteoporosis. The study will enroll roughly 750 patients and is designed to support an eventual application for FDA approval.Osteoporosis is a bone disease that occurs when the body loses too much bone, makes too little bone, or both. As a result, bones become weak, brittle, and highly susceptible to fractures, even from minor falls or bumps.<h2 class="st-heading-2">New Trial Outline</h2>The main measure of success in the upcoming trial will be how much bone density improves in the hip after one year of treatment. The company will also compare its pill to the existing injectable bone-building drug Forteo and include a smaller bone biopsy study in some patients. Patients who finish the main trial will continue in a follow-up study for up to two years to check longer-term safety and benefits.Entera expects to begin the trial in late 2026 and report top-line results in the second half of 2028 — about a year earlier than previously planned.Entera Bio is developing EB613 as the first oral version of a bone-building treatment for osteoporosis. All currently approved bone-building drugs must be given by daily injection and are used by only a small portion of patients who could benefit.The company’s earlier mid-stage study of the pill in 161 postmenopausal women met its goals, showing meaningful increases in bone density at the spine and hip. More recent early testing also showed that a single-tablet version performed similarly to the multi-tablet version used before and to the injectable Forteo.<h2 class="st-heading-2">How Did ENTX Retail Traders React?</h2>On Stocktwits, retail sentiment around ENTX stock jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.A Stocktwits user voiced optimism in the market potential of the drug, thanks to its ease of administration.<stembedurl>https://www.stocktwits.com/OldManLogan/message/657054690</stembedurl>The user also applauded the news as massive.<stembedurl>https://www.stocktwits.com/OldManLogan/message/657033145</stembedurl>According to data from Koyfin, the analyst covering ENTX rates it a ‘Buy’ with a price target of $9, representing a potential upside of about 643% from the stock’s last close.<a href="https://stocktwits.com/symbol/ENTX">ENTX stock</a> has gained about 7% this year.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/googl-stock-tumbles-after-losing-top-ai-talent-to-openai-anthropic/cZKMcYnR792">Did Google’s AI Ambitions Take A Hit Twice In A Week? What Investors Need To Know</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Entera Bio Ltd. logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Entera said that the FDA backed its plan for a single large late-stage clinical trial of its experimental once-daily pill, EB613, for postmenopausal women with osteoporosis.

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$3.20
Prev Close	$3.12
Open	$3.06
Dividend Yield	0.00%
50-Day Moving Average	$2.90
Beta	0.67
Avg. Volume	423,854.02
PE Ratio	-9.10

52-Week High	$4.20
52-Week Low	$0.91
Market Capitalization	$556.55M
EPS (Annual)	-$0.2476
Price to Book	21.71
Revenue Per Employee	$1,909.09

Feed

News

Sentiment

Earnings

Fundamentals

Info

ENTX Fundamentals